PGIM ETF Trust PGIM AAA CLO ETF (ARCA: PAAA)

Dernières nouvelles pour PGIM ETF Trust PGIM AAA CLO ETF (ARCA:PAAA)

Under normal circumstances, the Fund invests at least 80 percent of its investable assets in U.S. dollar-denominated collateralized loan obligations (CLOs) that are, at the time of purchase, rated AAA (or equivalent) by at least one nationally recognized statistical rating organization (NRSRO) or, if unrated, determined by the subadviser to be of comparable quality. Up to 20 percent of the Fund's investable assets may be invested in CLOs that are rated below AAA but not less that A minus by at least one NRSRO (or, if unrated, determined by the subadviser to be of comparable quality). The term investable assets refer to the Funds net assets plus any borrowings for investment purposes. The Funds investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions. The Fund is an actively managed exchange-traded fund (ETF) and therefore does not seek to replicate the performance of any specific index.

Prudential Core Gov Mm Fu

PGIM AAA CLO ETF

PGIM ETF Trust PGIM AAA CLO ETF

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.83) by 12.05 percent. This is a 12.05 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $138.37 million which beat the analyst consensus estimate of $137.00 million by 1.00 percent. This is a 4.32 percent increase over sales of $132.64 million the same period last year.

Earnings

Earnings Beats

News

LOVE

Lovesac Q1 EPS $(0.73) Beats $(0.83) Estimate, Sales $138.37M Beat $137.00M Estimate

<ul>
<li>Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy</li>
<li>Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing</li>
<li>Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares ("ADSs"), representing a premium of 55% to CureVac's three-month volume weighted average price of approx. $3.53 as of June 11, 2025</li>
<li>All-stock acquisition has potential to create long-term value for both companies' shareholders given their complementary capabilities, focus on mRNA innovation, and shared vision</li>
<li>Transaction is supported by CureVac's major shareholder dievini Hopp BioTech holding GmbH &amp; Co. KG and certain of its affiliates and expected to close in 2025&nbsp;</li>
</ul>

Biotech

Large Cap

Health Care

General

BNTX

CVAC

BioNTech Agrees To Acquire CureVac In All-stock Transaction

HC Wainwright &amp; Co. analyst Brandon Folkes assumes Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) with a Buy rating and announces Price Target of $7.

Price Target

Initiation

Analyst Ratings

CNTB

HC Wainwright & Co. Assumes Connect Biopharma Hldgs at Buy, Announces Price Target of $7

Tech billionaire and Shark Tank investor Robert Herjavec once credited a part-time retail job for equipping him with the tools that led to his eventual success in the world of business.
What Happened: Speaking to Lewis Howes on a podcast in February, Herjavec shared his inspiring story. When he was young, Herjavec went to Harry Rosen, a luxury clothing retailer in Canada, but the $1200 suit was too expensive for him. The shop attendant informed him that employees received 50% discounts on suits, so Herjavec took up a part-time job at the store.
Herjavec, who billionaire and fellow Shark Tank investor Mark Cuban described as being interested in <a href="https://www.benzinga.com/news/25/01/42898869/she-cant-do-math-and-hes-the-bad-guy-billionaire-mark-cuban-ranks-all-the-sharks-on-shark-tank">&#8220;pets and kids and stuff like that&#8221;</a> in his investments, shared: "The guy who owns the place called Harry Rosen … used to teach on Saturdays if you showed up an hour before the store opened." Herjavec showed up, unlike his colleagues, and found himself on the receiving end of a mentorship that covered everything from tailoring basics to client psychology.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45851993/mr-wonderful-kevin-oleary-says-he-was-once-told-by-a-ceo-to-shut-up-and-that-leveled-up-his-negotiation-skills-fellow-shark-mark-cuban-also-fle">Mr Wonderful, Kevin O&#8217;Leary, Says He Was Once Told By A CEO To &#8216;Shut Up&#8217; And That Leveled Up His Negotiation Skills — Fellow &#8216;Shark&#8217; Mark Cuban Also Flexes This Superpower</a>
Why It Matters: Highlighting the importance of what he learnt from Rosen, Herjavec said, "I would have paid him to teach me." "It was great, he taught me everything," he added. He later made headlines for his $30.2 million sale of BRAK Systems to AT&amp;T Canada and a private equity deal for his Herjavec Group in 2021.
"I&#8217;m not wealthy because of my knowledge of a task, I&#8217;m wealthy because of my knowledge of sales," he explained.
Despite his success, Herjavec continues to share new lessons that he learnt from others, including from an <a href="https://www.benzinga.com/startups/24/10/41600192/robert-herjavec-jokes-about-working-to-get-a-bigger-jet-than-mark-cubans-cubans-which-one-response-h">interaction with Cuban</a>, which taught him to refocus on his own goals instead of comparing his achievements with others'.
Last year, he also shared an anecdote about asking Cuban why he dresses like a "slob," to which Cuban replied, <a href="https://www.benzinga.com/personal-finance/25/05/45211673/billionaire-mark-cuban-was-asked-by-fellow-shark-tank-star-with-all-due-respect-why-do-you-dress-like-a-slob-he-responded-because-i-can">"because I can,"</a> highlighting the freedom and power that comes with accumulating a massive amount of wealth.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Shark Tank Host: My Parents &amp; I Escaped Communism With $20! THIS Unlocked Wealth for Me!" width="500" height="281" src="https://www.youtube.com/embed/M2e0WeBCYIs?start=2&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45889687/mark-cuban-predicts-ai-video-will-trigger-an-explosion-in-face-to-face-engagement-events-and-jobs-calls-it-the-milli-vanilli-effect">Mark Cuban Predicts AI Video Will Trigger &#8216;An Explosion&#8217; In Face-To-Face Engagement, Events And Jobs. Calls It &#8216;The Milli Vanilli Effect&#8217;</a></li>
</ul>
Photo courtesy: DFree / Shutterstock.com

Entrepreneurship

Shark Tank Star Robert Herjavec Says A Part-Time Job Made Him A Billionaire, Thanks To A Retail Mentor Who Taught Him How To Sell To The Wealthy

Macro Economic Events

Econ #s

Economics

INDA

India Consumer Price Index (YoY) For May 2.82% Vs. 3.00% Est.; 3.16% Prior

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) with a Buy and lowers the price target from $2.5 to $2.

HC Wainwright & Co. Maintains Buy on Westwater Resources, Lowers Price Target to $2

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1.png" alt="" class="wp-image-14317" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082317/Biogene-01-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Shares of Giant Biogene have plunged 30% in the month since it was accused of false advertising by rival Bloomage Biotech</li>
<li>Biogene's stock had more than doubled before the squabble on success of its collagen skincare products, making it vulnerable to an attack by its jealous rival</li>
</ul>
A fight between skincare brands owned by two of China's wealthiest women has mesmerized the country with saturation media coverage – and left one of the pair's formerly highflying stocks badly bruised.
In nearly a month since the skirmish began on May 17, shares of&nbsp;Giant Biogene Holding Co. Ltd.&nbsp;(2367.HK) have shed nearly 30% of their value, while&nbsp;Bloomage BioTechnology Corp. Ltd.&nbsp;(688363.SH), which initiated the dust-up, is up about 7%.&nbsp;
While the allegations have the potential to dent both companies' reputations, the selloff for Biogene's stock, in particular, seems overblown. In its latest annual results, Biogene reported its revenue soared 57.2% last year to 5.5 billion yuan ($765 million), fueling a 42.4% profit gain to 2 billion yuan. Bloomage is moving in the other direction, reporting its revenue fell 12% last year to 5.37 billion yuan, as its profit plunged 71% to 174 million yuan.
So, how did this squabble between rising beauty Biogene and a fading Bloomage begin?&nbsp;
The two are known for different core products. Bloomage's use hyaluronic acid (HA), which helps the skin retain moisture. Biogene uses recombinant collagen, which helps new cells grow in the skin layer. Recombinant collagen has become all the rage lately, fueling Biogene's rapid rise and prompting Bloomage to invest in that area as well.
The fight may also have a personal element, either real or perceived, with much of the media attention focused on presumed tension between Biogene founder Fan Daidi and Bloomage founder Zhao Yan, two of China's wealthiest women.
Fan, a biochemist and former visiting scholar at MIT, founded Biogene in 2000 and built it into an industry-leading brand in 2024, according to Euromonitor. Its star product, "Comfy Collagen Stick" ranked first in sales on e-commerce platforms in China during the June 18 shopping festival last year.
Zhao started out as a banker, launching Bloomage in 2001 with an initial focus on the raw materials market for HA. In 2017 her company acquired Revitacare, a French maker of HA compounds. Bloomage then launched Biohyalux, a heavily discounted skincare brand, and has 44% of the global market for HA raw materials.
Bloomage fired the first shot in the battle by publishing a 5,000-word report on its official WeChat account accusing nine equity research houses of playing up the merits of recombinant collagen over HA. "The HA industry has encountered lies and trampling, and has been described as ‘outdated,' ‘not as safe as a certain substance,' ‘not as biologically active as a certain substance,' ‘not as market-valuable as a certain substance,'" the report said, in a thinly veiled reference to recombinant collagen.
A media field-day ensued, with some reports likening Zhao to a Chinese empress taking aim at imperial powers from the West.
The battle heated up 10 days later when beauty influencer Hao Yu, better known as "Dr. Big Mouth," who made headlines after previously accusing an Estee Lauder product of false advertising and discrimination against Chinese, took aim at Biogene. In his attack, Hao claimed the company had violated China's cosmetic labeling regulations after he found only trace levels of recombinant collagen in a Comfy product he tested.
<h4 class="wp-block-heading">Quick rebuttal</h4>
The Comfy brand quickly released a statement saying that it had immediately conducted tests showing more than 0.1% collagen content, well above Hao's finding of just 0.0177%. Biogene also commissioned third party testing agents to conduct independent tests.
Bloomage admitted days later that Hao was effectively on its payroll through an investment relationship.
But that didn't end the fight. On June 4, Comfy shared the test results on its website, saying it had not made any "false or misleading" claims for its product. One of the testing agencies cited by Hao also accused him of using its test results without permission and issued a letter of apology cited by Biogene.
That didn't stop Hao from continuing the fight, accusing Biogene a day later of pressuring testing institutions not to test the company's recombinant collagen products. He added that he had received a message from one such major company refusing to conduct a test because it didn't want to get caught up in the slugfest.
There are plenty of signs that financial pressure on Bloomage may have been partly behind its attacks against its up-and-coming rival. Bloomage previously delayed publication of its full-year results for 2024, publishing them just two weeks before its first-quarter results. Its first-quarter financials were also weak, showing the company's revenue fell 20.7% year-on-year to 1 billion yuan.
In addition to weak financials, Bloomage is also being plagued by other issues, including executive departures, changes to its management team and an internal anti-corruption campaign.
Revenue from Bloomage's skincare products declined by 32% in 2024 to 2.57 billion yuan, accounting for 48% of total revenue. According to Wind data, the company's market value peaked at 140 billion yuan in 2021, and has shriveled since then to a current 26 billion yuan. In December 2024, it was removed from the CSI 300 Index for China's most important publicly traded companies.
Meanwhile, Giant Biogene has moved in the opposite direction. Its revenue and net income both doubled between 2022 and 2024, and the company raised $80 million in its 2022 Hong Kong IPO. Since then, its stock has more than doubled from its IPO price of HK$24.30 to its latest close of HK$60.60 on Wednesday, giving the company a market cap of about HK$61 billion ($7.8 billion). The company is in a market that will growth by an average 55% annually between 2022 and 2027 to reach 64.5 billion yuan, according to independent research.
Biogene is hardly the only Chinese company benefitting from recent positive publicity for recombinant collagen skincare products. Other beneficiaries include&nbsp;Jinbo Bio-Pharmaceutical,&nbsp;Guangdong Marubi Biotechnology&nbsp;(603983.SS), and&nbsp;FREDA&nbsp;(600223.SS). But as the Biogene-Bloomage dust-up shows, highflying companies – and their investors – often make easy targets for jealous rivals.

Asia

Global

Opinion

Giant Biogene Bruised In A 'Battle Of The Skincare Belles'

Keybanc analyst David Tarantino initiates coverage on Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with a Overweight rating and announces Price Target of $125.

Keybanc Initiates Coverage On Modine Manufacturing with Overweight Rating, Announces Price Target of $125

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) with a Buy and maintains $2.5 price target.

Reiteration

DGXX

HC Wainwright & Co. Reiterates Buy on Digi Power X, Maintains $2.5 Price Target

Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>), a global leader in electric vehicle (EV) charging and energy management solutions, today announced the expansion of its partnership with ENSOL EV, the e-mobility division of Texas-based Ensol Energy Solutions LLC. This next phase of the collaboration includes the deployment of Wallbox's Supernova DC fast chargers across key urban centers and transit corridors locations in Texas, Florida, and Georgia, three states experiencing rapid growth in EV adoption and charging demand.
Initial installations are scheduled to begin in the second half of 2025, with additional sites to follow through early 2026. The Supernova fast charger delivers up to 180 kW of power and includes integrated smart charging features for optimal energy distribution and uptime performance.
 &nbsp;

Wallbox Expands Partnership With ENSOL EV To Deliver Fast Charging Infrastructure In Texas, Florida, And Georgia

ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares at $3.43, per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.
&nbsp;
Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses. The PIPE is expected to close on June 16, 2025, subject to customary closing conditions. ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts primarily in support of ZYNLONTA&#xAE;&nbsp;clinical development as well as ZYNLONTA commercialization activities, working capital and general corporate purposes.

Offerings

ADCT

ADC Therapeutics Raises $100M in Private Stock Deal of 13M Shares at $3.5/Share And Warrants To Purchase 15.7M Shares At $3.43/Pre-funded Warrant to Boost Cancer Drug Development

WestPark Capital analyst Curtis Shauger maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Buy and raises the price target from $195 to $246.

ORCL

WestPark Capital Maintains Buy on Oracle, Raises Price Target to $246

On Wednesday, June 11, U.S. markets ended lower. The S&amp;P 500 slipped as investors grew wary over Middle East tensions and a reported embassy evacuation. A mild inflation report eased fears about tariff-driven price hikes, boosting hopes for future rate cuts.
Despite a tentative U.S.-China trade deal, skepticism lingered. Most sectors ended lower, with Amazon and Nvidia weighing heavily on the market.
According to economic data, the Bureau of Labor Statistics reported annual inflation at 2.4% in May, with core inflation steady at 2.8%, both slightly below expectations.
Most S&amp;P 500 sectors ended lower Wednesday, led by losses in materials, communication services, and consumer discretionary, while energy and utilities closed higher.
The Dow closed almost flat at 42,865.77, the S&amp;P 500 declined 0.27% to 6,022.24, and the Nasdaq slid 0.50% to 19,615.88.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Thursday, Japan&#8217;s Nikkei 225 closed 0.68% lower at 38,161.00, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.
Australia&#8217;s S&amp;P/ASX 200 was down 0.31% at 8,565.10, led by losses in the Materials, Metals &amp; Mining and Resources sectors.
India&#8217;s Nifty 50 was down 1.06% at 24,871.70, and the Nifty 500 slid 1.29% to 23,036.05.
China&#8217;s Shanghai Composite was up 0.01% at 3,402.66, and Shanghai Shenzhen CSI 300 fell 0.06% to 3,892.20.
Hong Kong&#8217;s Hang Seng closed the session 1.36% lower at 24,035.38.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 0.91%.
Germany&#8217;s DAX index declined 1.23%.
France&#8217;s CAC 40 fell 0.61%.
U.K.&#8217;s FTSE 100 index traded lower by 0.16%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading lower by 1.35% at $67.24/bbl, and Brent was down 1.35% at $67.47/bbl.
Oil prices fell as traders weighed rising Middle East tensions and a planned U.S.-Iran meeting following a sharp rally on supply disruption fears.
Natural gas rose 2.54% to $3.595.
Gold traded higher by 1.27% to $3,385.72, Silver slid 0.57% to $36.005, and Copper fell 0.37% to $4.7965.
Gold surged as safe-haven demand rose on Middle East tensions and tariff fears, while a weak dollar and uncertainty over U.S.-China trade talks boosted broader metal prices.
<h2 class="wp-block-heading">U.S. Futures</h2>
As of 5:45 AM ET, the Dow Jones futures were down 0.57%, the S&amp;P 500 declined 0.38%, and the Nasdaq 100 was down 0.31%.
<h2 class="wp-block-heading">Forex</h2>
As of 5:45 AM ET, the U.S. Dollar Index declined 0.71% to 97.96, USD/JPY was down 0.64% to 143.61, and USD/AUD slid 0.01% to 1.5381.
The dollar neared a 2025 low, and global stocks slipped as rising Middle East tensions and trade uncertainty pushed investors toward safe havens like gold, the yen, and the franc.
Photo via Shutterstock

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Slide, Dollar Softens On Inflation Data And Geopolitical Worries - Global Markets Today While US Slept

Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $80 price target.

PRAX

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $80 Price Target

Acquisition would offer TELUS Digital shareholders liquidity at a compelling value and enhance TELUS Digital's ability to effectively respond to changing market dynamicsCloser operational integration between TELUS and
<ul>
<li>Acquisition would offer TELUS Digital shareholders liquidity at a compelling value and enhance TELUS Digital's ability to effectively respond to changing market dynamics</li>
<li>Closer operational integration between TELUS and TELUS Digital to supercharge AI and SaaS transformation across telecommunications, health, agriculture and consumer goods sectors</li>
<li>TELUS Digital to continue as a key enabler to TELUS' growth strategy and operational efficiency</li>
</ul>

TIXT

TELUS Proposes Full Acquisition of TELUS Digital To Accelerate AI And SaaS Transformation Across Core Business Sectors

<ul>
<li>MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program</li>
<li>Study will evaluate a single dose of V181 for the prevention of dengue disease caused by any of the four serotypes of the dengue virus regardless of previous exposure</li>
</ul>

Merck Has Initiated MOBILIZE-1 Phase 3 Trial For Single Dose Of V181, An Investigational Quadrivalent Vaccine, For The Prevention Of Dengue Disease Caused By Any Of The Four Dengue Virus Serotypes. Recruitment For The Trial Has Begun, And The First Participants Are Now Enrolling In Singapore

Needham analyst Bernie McTernan reiterates Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from Hold to Hold.

CHWY

Needham Reiterates Hold on Chewyto Hold

CNX Resources Promotes Alan Shepard To President In Addition To His Current Role As CFO

The Trump administration has unveiled a new trade deal framework with China, but experts remain doubtful about its long-term viability and warn that the U.S. may be giving up its strategic advantage in the agreement.
What Happened: The deal aims to de-escalate tensions between the two nations, with both sides agreeing to roll back actions taken since the initial deal was struck on May 12. However, the deal is still pending approval from President Donald Trump and Chinese President Xi Jinping, <a href="https://www.politico.com/news/2025/06/11/trump-announced-another-deal-with-china-will-it-hold-00400288">reported</a> Politico.
Notably, the U.S. has agreed to further concessions, including easing restrictions on the export of certain sensitive products to China and resuming the issuance of student visas for Chinese nationals. In contrast, China has merely reiterated its earlier promise—made a month ago—to lift the blockade on critical mineral shipments. Despite the progress, experts are cautious. Derek Scissors, a senior fellow at the American Enterprise Institute, said, "This is another band aid.&#8221; He warns that China could easily reinstate the blockade on rare earths, a move that could severely impact global supply chains.
Former&nbsp;deputy assistant U.S. Trade Representative&nbsp;Emily Kilcrease&nbsp;believes the deal sets a &#8220;very dangerous precedent&#8221; by potentially weakening U.S. export controls.&nbsp;
Meanwhile, Marc Busch,&nbsp;a professor of international business&nbsp;diplomacy at Georgetown University, adds that China&#8217;s rhetoric remains unchanged, casting doubt on the sustainability of the trade truce. "China has always had this trump card, they know how to use it..,&#8221; cautioned Busch.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/25/06/45896615/us-recession-odds-tumble-to-23-on-crypto-betting-market-after-trump-confirms-china-trade-deal-softer-infla" target="_blank" rel="noreferrer noopener">US Recession Odds Tumble To 23% On Crypto Betting Market After Trump Confirms China Trade Deal, Softer Inflation Numbers</a>
Why It Matters: The recent deal follows the implementation of the Geneva trade consensus, which resulted in a 90-day pause on tariffs imposed on China. This agreement was reached <a href="https://www.benzinga.com/news/macro-notification/25/06/45876366/howard-lutnick-says-us-and-china-reached-a-framework-to-implement-geneva-consensus-following-trump-xi-call-csi-300-index-gains">after two days</a> of high-level discussions in London.
Meanwhile, Treasury Secretary&nbsp;Scott Bessent&nbsp;has suggested that the Trump administration may consider extending the current 90-day tariff pause beyond July 9 for the U.S.&#8217;s top trading partners. This extension, however, is <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45898040/scott-bessent-signals-willingness-to-extend-tariff-pause-for-good-faith-negotiations-trump-thinks-not-a-necessity">contingent </a>on the partners&#8217; &#8220;good faith&#8221; in ongoing trade negotiations.
These developments indicate a potential shift in the U.S.-China trade dynamic, with ongoing negotiations and agreements potentially shaping future trade relations.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/06/45891099/fartcoin-surges-40-in-a-week-on-coinbase-listing-outshines-dogecoin-shiba-inu" target="_blank" rel="noreferrer noopener">Fartcoin Surges 40% In A Week On Coinbase Listing, Outshines Dogecoin, Shiba Inu &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

'This Is Another Band-Aid,' Say Experts, Questioning Long-Term Viability And Efficacy Of US-China Trade Deal: 'China Always Had This Trump Card'

U.S. Marines will deploy to Los Angeles streets within 48 hours with authority to detain civilians, escalating federal-state tensions as California sues to block military involvement in immigration enforcement.
What Happened: President Donald Trump ordered Marines to deploy on Los Angeles streets amid ongoing protests against immigration raids, despite objections from California Governor Gavin Newsom, reported Reuters. The deployment marks the first <a href="https://www.benzinga.com/news/politics/25/06/45830221/gavin-newsom-calls-deployment-of-national-guard-in-los-angeles-unlawful-says-there-was-no-problem-until-trump-got-involved-serious-breach-of-state-sovereignty">federal activation of National Guard </a>without gubernatorial consent since 1965.
The Marines concluded specialized training, including de-escalation and crowd control techniques. Under Title 10 authority, they can temporarily detain individuals interfering with Immigration and Customs Enforcement operations or assaulting federal officers, according to Northern Command.
Army Major General Scott Sherman confirmed Marines will not carry live ammunition in rifles, but will carry live rounds.
The protests erupted in response to a series of immigration raids. ICE operations <a href="https://www.benzinga.com/markets/equities/25/06/45854643/home-depot-targeted-in-immigration-raids-amid-la-protests-threatening-customer-traffic">targeted multiple locations, </a>including The Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) stores in Westlake, Whittier, and Huntington Park.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45898547/openai-looks-to-raise-40-billion-from-global-investors-including-saudi-arabias-pif-indias-reliance-industries-to-accelerate-ai-models-and-stargate-report">OpenAI Looks To Raise $40 Billion From Global Investors Including Saudi Arabia&#8217;s PIF, India&#8217;s Reliance Industries To Accelerate AI Models And Stargate: Report</a>
Why It Matters: California filed suit Tuesday seeking a temporary restraining order, with hearings scheduled Thursday in San Francisco federal court.
California Attorney General Rob Bonta warned the federal troop deployment could violate the 1878 Posse Comitatus Act restricting military involvement in civilian law enforcement. The Trump administration contends the president has discretion to determine when &#8220;rebellion or danger of rebellion&#8221; requires a military response. Demonstrations spread nationwide to New York, Atlanta, Chicago, and other major cities. ICE operations averaged 2,000 daily arrests, significantly exceeding the 311 daily average under former President Biden. The escalation occurs as activists plan over 1,800 anti-Trump demonstrations Saturday coinciding with Trump&#8217;s 79th birthday. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45898644/tim-cook-explains-why-apples-f1-movie-bet-with-lewis-hamilton-serve-more-than-just-iphone-sales">Tim Cook Explains Why Apple&#8217;s &#8216;F1&#8217; Movie Bet With Lewis Hamilton Serves More Than Just iPhone Sales</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Joey Sussman / Shutterstock.com

Comments

PGIM ETF Trust PGIM AAA CLO ETF

Actualités

Dernières nouvelles pour PGIM ETF Trust PGIM AAA CLO ETF (ARCA:PAAA)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL